Using biological enrichment analyses, we determined that ZXD can treat NAFLD in part by modulating the key targets - HMGCR, SREBP-2, MAPK1, and NF-κBp65. This evidence concerns the gene MAPK1 and metabolic dysfunction-associated steatotic liver disease.